Simply Wall St weighs Novo Nordisk's outlook as Lilly and Viking competition grows

More peptides

1. Australian researchers weigh whether subsidizing GLP-1 drugs would make care fairer

   

   MXMedical Xpress Oct 21

   peptides typeshitPrices

   Australian researchers weigh whether subsidizing GLP-1 drugs would make care fairer

   Access to Ozempic, Wegovy and Mounjaro in Australia often comes down to who can pay, raising the question of public subsidies.

   Read at Medical Xpress
2. Ozempic and Mounjaro brought in $71B last year, more than OpenAI and Anthropic

   

   H@HealthcareAIGuy Oct 20

   peptides typeshitPrices

   Ozempic and Mounjaro brought in $71B last year, more than OpenAI and Anthropic

   HealthcareAIGuy says the two drugs earned about four times the AI labs' combined revenue, while only around 2% of people with obesity worldwide take them.

   See it on X
3. IQVIA starts tracking generic semaglutide as exclusivity ends in Canada

   

   IIQVIA Oct 20

   peptides typeshitPrices

   IQVIA starts tracking generic semaglutide as exclusivity ends in Canada

   Canada is one of the first big markets where semaglutide goes off patent. IQVIA plans ongoing updates on pricing, coverage and generic uptake.

   Read at IQVIA
4. Grand View Research sees peptide therapeutics nearing $295 billion by 2033

   

   MMM Mohan Oct 20

   peptides typeshitPrices

   Grand View Research sees peptide therapeutics nearing $295 billion by 2033

   The estimate, shared by M Mohan, starts from about $141 billion in 2025, with North America holding roughly 62% and semaglutide and tirzepatide leading.

   See it on X
5. BodySpec opens a storefront aimed at muscle loss from GLP-1 weight loss drugs

   

   LTLongevity Technology Oct 20

   peptides typeshitNews

   BodySpec opens a storefront aimed at muscle loss from GLP-1 weight loss drugs

   Longevity Technology reports BodySpec's new offering targets GLP-1 users worried about muscle, with body scans said to take about 12 minutes.

   See it on X
6. Dr. Beverly Tchang shares takeaways on amylin drugs from an AAFP talk in Nashville

   

   BGBeverly G. Tchang, MD Oct 20

   peptides typeshitResearch

   Dr. Beverly Tchang shares takeaways on amylin drugs from an AAFP talk in Nashville

   Obesity specialist Beverly Tchang posts her top three takeaways on the science of amylin based drugs after speaking at an AAFP event.

   See it on X